Transfusion Diagnostics Market Size, Competitive Landscape and Market Forecast - 2029

SKU: DMMDP858 | Last Updated On: Nov 14 2022 | Available Formats

> Transfusion Diagnostics Market Expected to reach a high CAGR of 9.68% By 2029: DataM Intelligence

Transfusion Diagnostics Information is segmented By Type (Instruments & Kit, Reagents, Others), By Application (Blood grouping, Disease screening, Others), By End User (Hospitals, Laboratories, Blood banks, Plasma fractionation facilities, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2022-2029

 

Transfusion Diagnostics Market was valued at US$ 3,955.29 million in 2021 and is estimated to reach US$ 6,707.35 million by 2029, growing at a CAGR of 9.68% during the forecast period (2022-2029).      

 Transfusion Diagnostics Market  - Strategic Insights

Metrics

Details

Market CAGR

9.68%

Segments Covered

By Product Type, By Transfusion Type, By Application, By End-User, and By Region

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights.

Fastest Growing Region

Asia Pacific

Largest Market Share 

North America

To Get a Free Sample Click here   

Blood transfusion is the process of transferring blood to the body. Transfusions are used for various medical conditions to replace lost blood components. Blood transfusions replace blood lost during surgery or due to a severe injury. A transfusion also may be done if the body can’t make blood properly because of an illness such as blood cancer.

Market Dynamics

The increasing demand for these diagnostic products is due to the rising incidence of blood cancer, serious injuries, and accidents. The rising number of surgeries, increasing research and development expenditure and growth in novel product launches are expected to drive market growth.

The increasing novel product launches and rising number of serious injuries and accident cases will drive market growth.     

The global market for transfusion diagnostics is primarily driven by the healthcare industry's demand for diagnostic products due to increasing chronic illnesses, including blood cancer, anemia, sickle cell anemia, kidney disease and serious infection such as transfusion-transmitted infections. The rising number of accidents, trauma and painful surgeries drive the market’s growth. For instance, in Aug 2022, QuidelOrtho Corporation announced receiving AABB “standards compliant” designation quality seal for an Ortho workstation developed by its subsidiary, Ortho Clinical, in vitro diagnostic services provider. This workstation is a blood testing system that has a 2-in-1 feature as it combines an incubator and a centrifuge.

Various funding, novel technological advancements, and the number of the latest, innovative product launches are increasing, leading to the high demand for these transfusion diagnostics. For instance, in July 2022, Roche launched Elecsys HCV Duo immunoassay, the first immunoassay that permits independent detection of hepatitis C virus antibodies and antigen status by a single human sample. This test can detect the infection at an early stage and can be used during the patient’s recovery phase or when showing chronic infection symptoms.

The high costs associated with transfusion diagnostics will hamper the market’s growth.  

However, high rates of quality-assured kits and instruments for transfusion diagnostics are the major factor restraining the growth. The unavailability of experienced professionals makes it difficult to handle the automated instruments and provide accurate results.

COVID-19 Impact Analysis

The pandemic has negatively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely impacted the healthcare industry. The transfusion diagnostics market has experienced huge losses due to COVID, as all the blood drives were canceled. People refused to get transfusions because of the spread of COVID and transfusion-transmitted infections. But now, the market participants are changing their long-term and short-term growth strategies by utilizing the research market and creating cutting-edge items to combat the pandemic. Various initiatives, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in Aug 2022, QuidelOrtho Corp, in vitro diagnostic innovative technology provider, announced joining the Alliance, a coalition established by the Association for Advancement of Blood and Biotherapies to strengthen the blood supply.

Segment Analysis

The disease screening segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)          

The disease screening segment is the highest market holder in the global transfusion diagnostics market. All the blood donated is screened to get evidence of the absence of any infection in the blood before releasing the blood and its components for clinical use, which is known as disease screening. Introducing serological assays that target virus-specific antigens and antibodies is very useful for detecting infection in donated blood, such as transfusion-transmitted infectious agents like TTIs, HIV, hepatitis B virus and hepatitis C virus. The latest nucleic acid amplification technology screening effectively minimizes the risk of infection. 

Disease screening dominates the market due to increased blood cancer cases globally. According to the World Health Organization, in 2022, approximately 1.24 million blood cancer cases occur globally annually. The rising number of people suffering from blood-related disorders, regulatory approvals and growing technological advancements or research/clinical trial studies drive the market’s growth. For Instance, in Jun 2022, Grifols, plasma-derived therapy and innovative diagnostic solutions developer, announced receiving the CE mark for Procleix Plasmodium Assay, 1st automatic nucleic acid test system specially designed for blood donors for patients related to malaria. 

Geographical Analysis

North America region holds the largest market share of the global transfusion diagnostics market.

North America dominates the global transfusion diagnostics market, primarily attributed to the rising prevalence of chronic ailments such as blood cancer, anemia, hemophilia, kidney disease and many more due to changing environments worldwide, established healthcare infrastructure, and higher investment in R&D activities contribute to North America’s rapid share growth. Moreover, its broad base patient population also contributes to the growth of its share. According to the World Health Organization, in 2022, more than 2 million people will suffer from anemia globally, affecting around 25% of the world’s population.

Moreover, the growing number of product launches is responsible for the market’s growth. Other factors, such as the high spending of GDP on healthcare, stimulate the market’s growth. Many key developments, technological advancements, collaborations and agreements are taking place in this region. For instance, in Sep 2022, Grifols, a plasma medicine manufacturer, announced its agreement with Canada’s national blood authority, Canadian Blood Services, to expand its self-sufficiency in essential plasma protein therapies and immunoglobulin medicines.

Competitive Landscape 

The transfusion diagnostics market is highly competitive with local and global companies’ presence. Ortho Clinical Diagnostics, Beckman Coulter, Quotient Limited, Abbott Laboratories, Diagast, Becton, Dickinson & Company, Immucor Inc., Grifols S.A., Bio-Rad Laboratories, F. Hoffmann-La Roche Ltd. and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in May 2022, Quidel Corporation announced transaction completion to combine with Ortho Clinical Diagnostics Holdings to form QuidelOrtho Corporation, in vitro diagnostic products and services provider company.

Ortho Clinical Diagnostics:

Overview:

Ortho Clinical Diagnostics is a company that provides in vitro diagnostic equipment for blood typing. It produces automated and semiautomated testing products and testing menu products. It was established in 1939 and is headquartered in New Jersey, United States. 

Product Portfolio:

Ortho Vision Platform: This platform comprises analyzers that test the compatibility of blood to make sure that patients receive the correct blood type during transfusion. Ortho vision products are designed for high-volume labs, allowing complex immunohematology testing, including serial dilutions, identifying particular cell antibodies and reflex tests.  

Key Development: In Sep 2021, Ortho Clinical Diagnostics, an in vitro diagnostic company, announced the launch of Immediate Spin Crossmatch (ISXM) that will provide aid in determining the incompatibility during blood transfusion between the recipients and donors. This serological test determines the incompatibility of ABO blood type between the recipient plasma and donor RBCs.

The global transfusion diagnostics market report would provide access to approximately 40+ market data tables, 45+ figures, and 200 (approximate) pages.  

Trending Topics

Tissue Diagnostics Market

Vehicle Diagnostics Market

Allergy Diagnostics Market

 

Did not find what you were looking for?Every 7 out of 10 customers request tailored reports. Get yours today!
We collate your requirements.
Our global research team is put into action.
We deliver, and make sure your endeavour is a success!

Buy This Report

20% Discount Applied*



Note*: For "Bundle/Bulk" Subscription of Reports,
please contact: [email protected]

Get your free sample proposal with a single click!

linkedinpinterest